Randomised, phase 1 evaluation of the safety, tolerability, pharmacokinetics and pharmacodynamics of iptacopan in healthy volunteers
British Journal of Pharmacology · 2026-06 · 183 (11) · 2874-2889
DOI: 10.1111/bph.70339 ↗At a glance
Randomisierte kontrollierte Studie in British Journal of Pharmacology, published online on 2026-02-17. Written by Irina Baltcheva and 5 co-authors. Institution: Novartis Pharma AG, Basel, Switzerland. Major MEDLINE topics: Benzoates, Piperidines, Pyridines. 42 references. The full text is freely available (open access, CC BY 4.0). Funded by: Novartis Pharma AG, Basel, Switzerland, Novartis Pharmaceuticals Corporation.
Abstract (original language)
Background and Purpose Overactivation of the alternative pathway (AP) underlies several diseases. Iptacopan is an oral, first‐in‐class, highly potent specific inhibitor of factor B, a key AP protease. Experimental Approach The analysis included data from two phase 1 randomised, volunteer‐blinded, placebo‐controlled studies: Study 1, a single ascending dose (SAD; 5–400 mg), multiple ascending dose (MAD; 25–200 mg twice daily), and food effect study of iptacopan in healthy volunteers; Study 2, a SAD (25–400 mg) study of iptacopan in healthy Japanese males. The objectives were to evaluate the safety and tolerability of iptacopan, and the pharmacokinetics/pharmacodynamics of SAD and MAD doses. Key Results In Study 1 (n = 100) and Study 2 (n = 30), iptacopan was rapidly absorbed; pharmacokinetic variability was low, with a half‐life between 18.4 and 25.0 h across steady‐state MAD doses, and iptacopan exhibited target‐mediated drug disposition behaviour. Japanese and non‐Japanese healthy volunteers had similar pharmacokinetics/pharmacodynamics. Food intake did not affect pharmacokinetics. Iptacopan 200 mg twice daily showed the highest and most persistent AP inhibition; ~67% AP inhibition remained 24 h after the last dose, while ex vivo classical complement pathway activation was not impaired. This dose also provided the highest proportion of volunteers achieving EC90 values for the complement biomarkers Wieslab® assay in serum, plasma Bb and sC5b‐9. Iptacopan was well tolerated across doses. Conclusions and Implications These results characterise the pharmacokinetics/pharmacodynamics of iptacopan in healthy volunteers; the data helped build semi‐mechanistic population pharmacokinetic/pharmacodynamic models, which guided the accelerated clinical development of iptacopan.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Novartis Pharma AG, Basel, Switzerland.
- Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, USA.
- Novartis Institutes for BioMedical Research, Basel, Switzerland.
- Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
Funding
- Novartis Pharma AG, Basel, Switzerland
- Novartis Pharmaceuticals Corporation
Cite
APA
Baltcheva, I., Junge, G., Kulmatycki, K., Schmouder, R., Schubart, A., & Valentin, M. A. (2026). Randomised, phase 1 evaluation of the safety, tolerability, pharmacokinetics and pharmacodynamics of iptacopan in healthy volunteers. British Journal of Pharmacology, 183(11), 2874-2889. https://doi.org/10.1111/bph.70339
Vancouver
Baltcheva I, Junge G, Kulmatycki K, Schmouder R, Schubart A, Valentin MA. Randomised, phase 1 evaluation of the safety, tolerability, pharmacokinetics and pharmacodynamics of iptacopan in healthy volunteers. British Journal of Pharmacology. 2026;183(11):2874-2889. doi:10.1111/bph.70339
BibTeX
@article{Baltcheva2026,
author = {Baltcheva, Irina and Junge, Guido and Kulmatycki, Kenneth and Schmouder, Robert and Schubart, Anna and Valentin, Marie-Anne},
title = {Randomised, phase 1 evaluation of the safety, tolerability, pharmacokinetics and pharmacodynamics of iptacopan in healthy volunteers},
journal = {British Journal of Pharmacology},
year = {2026},
volume = {183},
number = {11},
pages = {2874--2889},
doi = {10.1111/bph.70339}
}
EUVIMED